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ABSTRACT
Malignant melanoma requires precise resection in order to avoid metastatic 
recurrence. We report here that the telomerase-dependent, green fluorescent protein 
(GFP)-containing adenovirus OBP-401 could label malignant melanoma with GFP 
in situ in orthotopic mouse models. OBP-401-based fluorescence-guided surgery 
(FGS) resulted in the complete resection of malignant melanoma in the orthotopic 
models, where conventional bright-light surgery (BLS) could not. High-dose 
administration of OBP-401 enabled FGS without residual cancer cells or recurrence, 
due to its dual effect of cancer-cell labeling with GFP and killing.
INTRODUCTION
Despite recent advances, the current therapeutic 
approaches in melanoma are not satisfactory and intensive 
research in this area is still required [1].
Cancer surgery requires precise identification 
of tumor margins. Green fluorescent protein (GFP) 
fluorescence can intensely illuminate even single cells 
in vivo [2, 3]. Introducing and selectively activating 
the GFP gene in tumors in vivo was made possible by 
the development of OBP-401, a telomerase-dependent, 
replication-competent adenovirus expressing GFP. In an 
intraperitoneal nude mouse model of disseminated human 
colon cancer, fluorescence-guided surgery (FGS) enabled 
resection of tumor nodules labeled with GFP by OBP-401 
[4]. Recurrent tumor nodules brightly expressed GFP, 
indicating that initial OBP-401-GFP labeling of peritoneal 
disease was genetically stable [5].
Glioblastoma multiforme (GBM) is one of the 
most invasive of cancers and is not totally resectable 
using standard bright-light surgery (BLS) or current FGS 
strategies. We previously developed a curative strategy 
for FGS of GBM using high-dose OBP-401 to selectively 
label GBM with GFP. OBP-401-based FGS enabled 
curative resection of GBM without recurrence for at least 
150 days, compared to less than 30 days with BLS [6].
OBP-401-based FGS resulted in superior resection 
of soft-tissue sarcoma (STS) in an orthotopic nude mouse 
model, compared to BLS. High-dose OBP-401 enabled 
FGS without residual sarcoma cells or local or metastatic 
recurrence, due to its dual effect of cancer-cell labeling 
with GFP and killing. High-dose OBP-401 based-FGS 
improved disease-free survival as well as preserved 
muscle function compared with BLS [7].
OBP-401 was used to label the cancer cells of a 
pancreatic cancer patient-derived orthotopic xenograft 
(PDOX) nude mouse model. The PDOX was previously 
grown in a red fluorescent protein (RFP) transgenic mouse 
that stably labeled the PDOX stroma cells bright red. The 
color-coded PDOX model enabled FGS to completely 
resect the pancreatic tumors including stroma. Dual-
colored FGS significantly prevented local recurrence, 
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which bright-light surgery or single-color FGS could 
not. FGS, with color-coded cancer and stroma cells 
has important potential for improving the outcome of 
recalcitrant-cancer surgery [8].
OBP-401-FGS of tumors in the lung enabled complete 
lung tumor resection with no residual fluorescent tumor [9].
OBP-401 tumor illumination enabled effective FGS 
of an orthotopic mouse model of human osteosarcoma 
model as well as eradication of residual osteosarcoma 
cells after BLS. OBP-401-FGS significantly inhibited 
local recurrence and lung metastasis after surgery thereby 
prolonging survival [10].
In the present report, we demonstrate that OBP-401 
GFP labeling in situ enables precise FGS of malignant 
melanoma without recurrence.
RESULTS AND DISCUSSION
OBP-401 targets malignant melanoma cell lines 
with GFP in vitro
Time-course imaging demonstrated that OBP-401 
labeled RFP-expressing Mel526, FEMX1, LOMVIXI, 
MV3 malignant melanoma cells with GFP (Figure 1A). 
GFP fluorescence, after OBP-401 targeting of Mel526, 
FEMX1, LOMVIXI, MV3 cells, became stronger each 
day from day 2 to day 7 (Figure 1A, 1B).
Orthotopic malignant melanoma model
An orthotopic malignant melanoma tumor model was 
established with FEMX1-RFP cells implanted in the femoral 
skin where FEMX1-RFP cells produced a nodular tumor 
(Supplementary Figure S1A, S1B). The orthotopically-
growing malignant melanoma cells invaded the quadriceps 
femoris muscle and metastasized to lymph nodes similar 
to the clinical course of melanoma (Supplementary Figure 
S1C). Tumor growth was visualized by RFP fluorescence 
(Supplementary Figure S1C).
Bright-light surgery results in residual 
melanoma cells in the orthotopic model
We performed bright-light surgery (BLS) on the 
orthotopic malignant melanoma model (Figure 2A, 
Supplementary Figure S2A). Due to inability to clearly 
visualize the tumor margins, extensive RFP-expressing 
malignant melanoma cells remained after BLS (Figure 
2A, 2D).
OBP-401-based fluorescence-guided surgery 
(OBP-401-FGS) of orthotopic melanoma using a 
stationary imaging system
The orthotopic tumor growing in the femoral 
skin (100 mm3, diameter; 6 mm) was resected 3 days 
after i.t. injection of OBP-401 (1×108 PFU) (Figure 2B, 
Supplementary Figure S2B). OBP-401 conferred GFP 
fluorescence of the orthotopic melanoma which was 
sufficiently bright to perform complete resection using the 
OV100 whole body imaging system (Figure 2B). Tumor 
imaging showed that OBP-401 GFP labeling co-localized 
with tumor RFP fluorescence (Figure 2B, 2C). OBP-
401-GFP-targeted FGS resulted in no detectable residual 
melanoma cells (Figure 2B, 2D).
OBP-401-FGS of malignant melanoma using 
a hand-held portable fluorescence imaging 
system
OBP-401-GFP targeting enabled the use of the 
Dino-Lite hand-held portable fluorescence imager [11] 
for FGS (Figure 3). OBP-401-GFP labeling for four days 
made the tumor margin much clearer than under bright-
light (Figure 3A). Using the Dino-Lite, the tumor margin 
was clearly visualized enabling complete resection of 
the malignant melanoma (Figure 4B, Supplementary 
Movie S1). Fluorescence imaging showed that there 
were no residual cancer cells after OBP-401 FGS of 
malignant melanoma with the Dino-Lite (Figures 3, 4).
OBP-401-FGS targets residual melanoma cells 
in the orthotopic model after BLS and enables 
complete resection
OBP-401 was intratumorally injected 3 days 
before BLS of FEMX1-RFP melanoma growing in the 
femoral skin (Supplementary Figure 3). OBP-401 enabled 
detection of the residual cancer cells at the single cell level 
in the surgical bed after BLS using a whole body imaging 
system (OV100) (Figure 4A). After OBP-401-FGS, there 
were no detectable residual cancer cells (Figure 4B, 4C). 
OBP-401 delineated the precise margins between cancer 
and normal tissue. OBP-401 enabled determination 
whether there were residual cancer cells at the single-
cell level after FGS using confocal microscopy (FV1000) 
(Figure 4D, 4E).
High-dose OBP-401 kills melanoma cells 
growing orthotopically in vivo, thereby enabling 
minimal surgery
High-dose OBP-401 targeted and killed Mel526-
RFP, FEMX1-RFP, LOMVIXI-RFP, MV3-RFP cells in 
a dose-dependent manner in vitro (Figure 5). Therefore, 
we determined whether high-dose OBP-401 (2×108 
PFU)FGS enabled minimally-invasive surgery of 
melanoma compared with BLS or low-dose FGS. High-
dose OBP-401 injected i.t. significantly reduced the size 
of tumors compared with untreated control tumors or 
low-dose OBP-401 (Figure 6A, 6B). The surgical area 
necessary for high-dose OBP-401 FGS was smaller than 
that for BLS or low-dose OBP-401 FGS (Figure 6C, 6D). 
The weight of tumor resected by high-dose OBP-401 FGS 
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Figure 1. OBP-401 targets human malignant melanoma cell lines with GFP in vitro. RFP-expressing human malignant melanoma 
cell lines, Mel526, FEMX1, LOMVIXI, MV3 were seeded on 6 well plates (1×105 cells well). OBP-401 was added at the indicated multiple of 
infection (MOI) 24 hours after cell seeding. Images were acquired with an FV1000 confocal laser scanning microscope (Olympus). A. Time-
course images of Mel526, FEMX1, LOMVIXI, MV3 cells 2, 3, and 4 days after infection with OBP-401, at indicated MOIs.
(Continued )
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Figure 1 (Continued ): B. Histograms show the frequency of GFP-expressing Mel526, FEMX1, LOMVIXI, MV3 cells at indicated days 
after infection with OBP-401. Data are shown as average ± SD. N = 5. Scale bars = 500 μm.
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Figure 2. Comparison of OBP-401-targeted fluorescence-guided surgery with bright-light surgery for orthotopic 
malignant melanoma using a stationary imaging system. RFP-expressing FEMX1 cells (5×106) in 20 μl Matrigel (BD) were 
inoculated in the femoral skin of nude mice (5 weeks old). OBP-401 (1×108 PFU) was injected intratumorally when tumors reached 
approximately 100 mm3 (6 mm diameter). A. Representative whole-tumor images of mock-infected REP-expressing orthotopic melanoma 
before and after bright-light surgery (BLS). B. Representative whole-tumor images of OBP-401-GFP labeled, RFP-expressing orthotopic 
malignant melanoma before and after OBP-401-based fluorescence-guided surgery (OBP-401 FGS). 
(Continued )
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was less than that by BLS or low-dose OBP-401 FGS due 
to the cytotoxic effects of OBP-401 (Figure 6E).
OBP-401 based FGS resulted in  
recurrence-free surgery
Fluorescence imaging showed that eight of twelve 
mice that underwent BLS had RFP-expressing local 
recurrences (Figure 7A, 7D and 7E). In contrast, there was 
no local recurrence in twelve  mice which received low-
dose OBP-401-FGS (Figure 7B, 7D and 7E). Moreover, 
there was also no local recurrence in ten mice which 
received minimal surgery after high-dose administration 
of OBP-401 (Figure 7C, 7D and 7E) (Table 1).
Labeling tumors with OBP-401 for FGS has none of 
the weaknesses of non-genetic labeling, particularly loss 
of label over time and limited expression of the marker 
used for labeling. OBP-401 may be a general method for 
labeling tumors that express telomerase, which are the vast 
majority, that could have broad application for FGS.
A Phase I clinical trial of i.t. injection of OBP-
301, the parent of OBP-401, in patients with advanced 
solid tumors was well tolerated [12]. Melanoma occurs 
intracutaneously, and therefore OBP-401 could be directly 
delivered and be tested in the clinic in the near future.
Concepts and strategies of highly-selective tumor 
targeting that were previously developed [13–17] can take 
advantage of adenoviral targeting of tumors, including 
Figure 2 (Continued ): C. Representative whole-tumor images of a tumor resected by BLS and a tumor resected by OBP-401 FGS using 
the OV100 whole body imaging system. D. Bar graph shows the comparison of fluorescent area in the surgical bed after BLS or OBP-401 
FGS (left). Bar graph shows the comparison of fluorescence intensity in the surgical bed after BLS or OBP-401 FGS (right). Fluorescent 
area and fluorescence intensity are calculated with ImageJ software. Data are shown as average ± SD. N = 12. Scale bars = 1 cm.
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Figure 3. OBP-401 based FGS of melanoma using the Dino-Lite hand-held portable fluorescence scope. A. Representative 
whole tumor images of OBP-401-GFP labeled, RFP-expressing orthotopic malignant melanoma before and after OBP-401-FGS using the 
Dino-Lite hand-held fluorescence scope. B. Step-by-step procedure for OBP-401 based FGS of malignant melanoma using the Dino-Lite 
hand-held-fluorescence scope.
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Figure 4. OBP-401 targeting visualizes residual malignant melanoma cells after BLS. A. Representative high-magnification 
images of the surgical bed of orthotopic malignant melanoma after BLS. B. OBP-401 targeting enabled visualization of residual tumor 
after BLS and results in complete resection. Representative high-magnification images of surgical bed after FGS of malignant melanoma. 
C. Step-by-step procedure of OBP-401 based FGS of residual malignant melanoma after BLS using the Dino-Lite hand-held fluorescence 
scope. D. Representative images of resected malignant melanoma nodule by FGS. Images were acquired with the OV100. E. Representative 
single-cell level images of resected malignant melanoma nodule after FGS. Images were acquired with the FV1000 confocal microscope.
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Figure 5. OBP-401 kills human malignant melanoma cell lines in vitro. A. Representative images of RFP-expressing human 
malignant melanoma cell lines, Mel526-RFP, FEMX1-RFP, LOMVIXI-RFP, and MV3-RFP, 7 days after targeting with OBP-401 at a MOI 
of 5, 15, and 30. B. Bar graphs show the surviving fraction of Mel526-RFP, FEMX1-RFP, LOMVIXI-RFP, and MV3-RFP cells 7 days 
after targeting with OBP-401 in vitro. The number of live cells was counted. Data are shown as average ± SD. N = 5. Scale bars = 250 μm.
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Figure 6. OBP-401 enables minimal precise surgery for orthotopic melanoma. A. Representative whole-tumor images of 
orthotopic malignant melanoma before and after mock-infection or before and after i.t. administration of low-dose OBP-401 (1×108 
PFU) or high-dose OBP-401 (at 3×108 PFU). B. Bar graphs show the fluorescence intensity of a control tumor and low-dose or high-
dose OBP-401-targeted tumors (left). Fluorescent area is calculated with ImageJ software. Bar graphs show the fluorescence area of 
control tumor and low-dose or high-dose OBP-401-targeted tumors (right). Fluorescence intensity is calculated with ImageJ software. 
Data are shown as average ± SD. N = 10. C. Representative images of surgical area after BLS (upper) and low-dose (middle) or high-dose 
OBP-401-FGS (lower). Bright field images (left panels) and fluorescence images (right panels). D. Bar graphs show the comparison of 
surgical area after BLS, low-dose FGS, or high doe FGS. E. Bar graphs show the comparison of tumor weight after BLS, low-dose FGS, 
or high-dose FGS. Data are shown as average ± SD. N=10, *p<0.05.
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Figure 7. OBP-401-based FGS prevents local recurrence. A. Representative whole-body images of orthotopic malignant 
melanoma 90 days after BLS. B. Representative whole body images of orthotopic malignant melanoma 90 days after low-dose OBP-
401-FGS. C. Representative whole body images of orthotopic malignant melanoma 90 days after precise minimal FGS with high-dose 
administration of OBP-401. Upper panels in A, B, C: brightfield; lower panels: fluorescence.
(Continued )
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Figure 7 (Continued ): D. Comparison of fluorescent areas of recurrent tumors after BLS, low-dose OBP-401-FGS, or high-dose OBP-
401-FGS (left panel). Fluorescent area is calculated with ImageJ software. Comparison of fluorescence intensity of recurrent tumors after 
BLS, low-dose OBP-401-FGS, or high-dose OBP-401-FGS (right panel). Fluorescence intensity is calculated with ImageJ software. Data 
are shown as average ± SD. N = 10. E. Kaplan-Meyer curves show the over-all survival after BLS or OBP-401-FGS.
tissue-selective therapy which focuses on unique 
properties of normal and tumor tissues [13, 15, 18]. OBP-
401 can possibly overcome de-differentiation of a tumor 
leading to resistance to targeted chemotherapy, because the 
targeted protein or pathway may no longer be expressed 
[18], since OBP-401 does not depend on such targets 
[15], but depends only on telomerase expression which 
is expected to be stable in cancer cells. OBP-401 may 
also be effectively combined with teratogens which could 
selectively effect cancer cells that are dedifferentiated [14]. 
Since OBP-401 can decoy quiescent cancer cells to begin 
to cycle [19], OBP-401 could be effectively combined 
with agents which selectively target proliferating cancer 
cells [16], where normal cells are protected by agents 
which induce wild type p53 [17].
Other fluorescence methods of labeling tumors are 
also available. Fluorescence labeling at long wavelengths, 
such as near infrared (NIR), enables potential greater 
depth of visualization of the label, but such non-genetic 
methods will not label recurrent tumors [20].
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MATERIALS AND METHODS
GFP-expressing telomerase-specific adenovirus
In OBP-401, the promoter element of the human 
telomerase reverse transcriptase (hTERT) gene drives the 
expression of E1A and E1B genes, linked to an internal 
ribosome entry site, for selective replication only in cancer 
cells. The GFP gene is driven by the CMV promoter 
inserted in OBP-401 [21].
Cell line and cell culture
Red fluorescent protein-expressing human 
malignant melanoma cell lines Mel526-RFP, FEMX-
RFP, LOMVIXI-RFP, and MV3-RFP (AntiCancer, Inc., 
San Diego, CA) were maintained and cultured in DMEM 
medium with 10% fetal bovine serum (FBS) and 5% 
penicillin/streptomycin.
In vitro imaging
Time-course imaging of OBP-401-GFP labeling 
of melanoma cell lines was performed with an FV1000 
confocal laser-scanning microscope (Olympus, Tokyo, 
Japan).
Animal experiments
Athymic (nu/nu) nude mice (AntiCancer, Inc., San 
Diego, CA) were kept in a barrier facility under HEPA 
filtration. Mice were fed with autoclaved laboratory rodent 
diet (Tecklad LM-485, Western Research Products). 
All animal studies were conducted in accordance with 
the principles and procedures outlined in the National 
Institutes of Health Guide for the Care and Use of 
Laboratory Animals under Assurance Number A3873– 01.
Orthotopic melanoma model
RFP-expressing FEMX1 cells (5 × 106) suspended 
in Matrigel (20 uL)were inoculated into the left femoral 
skin of athymic nude mice (5-weeks old). Tumor 
progression was monitored by noninvasive fluorescence 
imaging (OV100) [22].
OBP-401 based fluorescence-guided surgery 
(OBP-401-FGS)
All animal procedures were performed under 
anesthesia using s.c. administration of a ketamine mixture 
[10 μl ketamine HCl, 7.6 μl xylazine, 2.4 μl acepromazine 
maleate, and 10 μl PBS]. Orthotopic melanoma labeled 
with GFP by OBP-401 was observed with noninvasive 
fluorescence imaging using the OV100 Small Animal 
Imaging System (Olympus) [22]. OBP-401 FGS was 
performed using either the OV100 or a Dino-Lite hand-held 
fluorescence scope (Dino-Lite digital camera, AM4113T-
GFBW Dino-Lite Premier; AnMo Electronics Corp., 
Hsinchu, Taiwan) [11]. After surgery, the presence of cancer 
cells was observed with the OV100 and Dino-Lite. If there 
were residual cancer cells, an additional resection was 
performed [7].
Statistical analysis
Data are shown as means ± SD. For comparison 
between two groups, significant differences were 
determined using the Student’s t-test. For comparison 
of more than two groups, statistical significance was 
determined with a one-way analysis of variance (ANOVA) 
followed by a Bonferroni multiple group comparison test. 
Pearson chi-square analysis was used to compare the rate 
of local recurrence between BLS and OBP-401-FGS. 
Statistical analysis for disease-free survival and over-all 
survival was performed using the Kaplan-Meier test along 
with log-rank test. Pearson chi-square analysis was used 
to evaluate the rate of local recurrence and lung metastasis 
between BLS and OBP-401-FGS. P values of < 0.05 were 
considered significant.
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